---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-067387"
form_type: "8-K"
ticker: "COCH"
cik: "0001840877"
company_name: "Envoy Medical, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:08:38.553532+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Envoy Medical Q2 revenue $68k, cash $1.7M; Acclaim CI pivotal trial goal by end-2024

## Summary
- Revenue $68k (Q2 2024) vs $63k prior year; revenue from two Esteem units offset by battery sales decline.
- R&D expenses rose $438k to $2.6M due to increased headcount for Acclaim CI pivotal study preparation.
- Three EFS participants completed 18-month follow-up; all show CIQOL improvement, no SADEs/UADEs reported.
- System noise mitigations implemented; two participants used hearing aid with Acclaim for better SNR.
- Company maintains goal to submit IDE in coming months and start pivotal trial by year-end 2024; commercialization targeted by end-2026.

## SEC filing metadata
- accession: 0001213900-24-067387
- form_type: 8-K
- ticker: COCH
- cik: 0001840877
- company_name: Envoy Medical, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840877/000121390024067387/0001213900-24-067387-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840877/000121390024067387/ea0211068-8k_envoy.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-067387
- JSON: https://secwatch.observer/filing/0001213900-24-067387.json
- Plain text: https://secwatch.observer/filing/0001213900-24-067387.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.